Many thanks and congratulations to silke gillessen and aurelius omlin and the superb #APCCC24 team on another spectacularly successful meeting! A clear consensus (unanimously) a great success 😀

Debate: how to best manage a fit patient with high-risk localised and locally advanced #prostatecancer ? Presented by Jason Efstathiou, MD, DPhil, Harvard Medical School. #APCCC24 Written coverage by Rashid K. Sayyid University of Toronto. > bit.ly/3y6wIJC Advanced Prostate Cancer Consensus Conference.

Great session and great panel to discuss the ⁦The Lancet⁩ Prostate Cancer Commission. Many thanks to #APCCC24 for featuring prominently. Will be a fantastic launch pad for new initiatives. ⁦The ICR⁩ thelancet.com/pdfs/journals/…

Thank you very much aurelius omlin and kudos to you, silke gillessen and the entire Advanced Prostate Cancer Consensus Conference team for having OncoAlert 🚨involved. An honour and a pleasure to be able to for part of this AMAZING meeting in Lugano!

Radical prostatectomy is good option in selected high risk and locally advanced (T3) PCA patients. #SPCG15 RCT study will give more data. Role of eLND under discussion. PSMA-PET sensitivity and specificity still not optimal. #APCCC24

silke gillessen Indeed, you are a wonderful ambassador of Advanced Prostate Cancer Consensus Conference

Congrats @SilkeGillessen & aurelius omlin on a truly outstanding Advanced Prostate Cancer Consensus Conference #APCCC24

Gran reunión
🇦🇷 #UrooncoArgentina #APCCC24 OncoAlert Advanced Prostate Cancer Consensus Conference Uromigos GU Cast | Urology podcast! silke gillessen Dr. Tomás Soulé EAU Edu Platform UROONCO Urooncologia.arg Neeraj Agarwal, MD, FASCO Harold Somerville UroTarget

#APCCC24 Advanced Prostate Cancer Consensus Conference 👉 most panelists favor continuing Lutetium-177 RLT Rx to complete 6 cycles even after PSA/clinical/radiological response after 4 cycles in mCRPC #prostatecancer OncoAlert PCF Science silke gillessen

And it’s a wrap! It’s been a wonderful and exciting conference. Thanks silke gillessen aurelius omlin and Advanced Prostate Cancer Consensus Conference !

Let’s meet all in 2026 for #APCCC26

And next year for APCCC Diagnostics led by Ken Herrmann and prof. Stefano Fanti

#APCCC24

💫🌟At #APCCC24 , the debate continues on the optimal number of 177Lu-PSMA therapy cycles:
Advanced Prostate Cancer Consensus Conference OncoAlert
silke gillessen aurelius omlin
🔄 For patients responding after 4 cycles:
   - Majority vote to continue to 6 cycles: 📊 Yes: 43%, Selectively: 39%
🚫 If no significant

💫🌟Monitoring response during 177Lu-PSMA therapy is a hot topic at #APCCC24 :
Advanced Prostate Cancer Consensus Conference OncoAlert
silke gillessen aurelius omlin
🎯 70% recommend imaging for all patients to track therapy response.
🔍 22% opt for imaging only in selected cases.
✅ Ensuring timely adjustments and

For patients who have completed 6 cycles of 177Lu-PSMA treatment and meet relevant PET criteria, the majority opinion (59%) supports re-treatment only if there was a response duration of more than 6 months.

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin OncoAlert Daniel Castellano

⭕️Después de 4 ciclo de 177LU-PSMA con respuesta cual es la recomendacion
🎯SI #CONSENSO
🇦🇷UrooncoArgentina #APCCC24 OncoAlert Advanced Prostate Cancer Consensus Conference Uromigos GU Cast | Urology podcast! silke gillessen Dr. Tomás Soulé EAU Edu Platform UROONCO Harold Somerville Neeraj Agarwal, MD, FASCO Asociación Argentina de Oncología Clínica (AAOC) UroTarget

In patients showing a response to 177Lu-PSMA therapy after 4 cycles, there's a consensus (76% agreement) for continuing to complete the 6 cycles if significant remaining uptake is noted. Conversely, if there’s no remaining uptake, most votes lean towards not continuing (57%

Dear Colleagues
Grab your morning coffee☕️Get comfortable and get ready to have some FUN with GU Cast | Urology podcast! , Uromigos and OncoAlert 🚨as we have some amazing conversation right next to Lake Lugano at #APCCC24 🇨🇭

We Love this Lot and dont forget to follow:
Declan Murphy🇦🇺

For patients on treatment with 177Lu-PSMA, the preferred imaging modality for response monitoring, as voted, is PSMA PET plus diagnostic CT (with iv iodine contrast), receiving 41% of the votes. There is no clear consensus!

#APCCC24 Advanced Prostate Cancer Consensus Conference silke gillessen aurelius omlin

⭕️Como influye la información genómica en definir tratamiento 1era linea❓
🎯SI #CONSENSO
🇦🇷UrooncoArgentina #APCCC24 OncoAlert Advanced Prostate Cancer Consensus Conference Uromigos GU Cast | Urology podcast! silke gillessen EAU Edu Platform UROONCO Harold Somerville Neeraj Agarwal, MD, FASCO Dr. Tomás Soulé UroTarget

⭕️Cual es el paciente que debe realizarse una test germinal #smehereditarios
🧬Historia familiar.
🎯Edad de presentación.
🧬Asesoramiento GENETICO
🇦🇷 #UrooncoArgentina #APCCC24 OncoAlert Advanced Prostate Cancer Consensus Conference GU Cast | Urology podcast! silke gillessen EAU Edu Platform UROONCO Neeraj Agarwal, MD, FASCO UroTarget